We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
Read MoreHide Full Article
Adaptive Biotechnologies (ADPT - Free Report) shares ended the last trading session 5.8% higher at $13.17. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19.9% loss over the past four weeks.
Adaptive Biotechnologies’ stock price gain can be attributed to the positive investor mindset regarding the potential of its pipeline. The company is advancing a portfolio focused on immune-profiling diagnostics and immune-driven drug discovery. Its lead commercial product, clonoSEQ, is used to monitor minimal residual disease in hematologic cancers such as multiple myeloma and leukemia, and the company continues to expand its clinical adoption and regulatory indications. Additionally, the company’s Immune Medicine platform aims to discover T-cell receptor-based therapeutics targeting infectious diseases, cancer and autoimmune conditions. The company is also progressing research programs to identify disease-specific immune responses, which could support future diagnostics and therapeutic development.
This life-sciences research company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of +20%. Revenues are expected to be $61.84 million, up 17.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Adaptive Biotechnologies, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ADPT going forward to see if this recent jump can turn into more strength down the road.
Adaptive Biotechnologies is part of the Zacks Medical - Biomedical and Genetics industry. AnaptysBio, Inc. (ANAB - Free Report) , another stock in the same industry, closed the last trading session 1.6% higher at $64.81. ANAB has returned 16.2% in the past month.
For AnaptysBio, the consensus EPS estimate for the upcoming report has changed +34.5% over the past month to -$0.72. This represents a change of +43.8% from what the company reported a year ago. AnaptysBio currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT - Free Report) shares ended the last trading session 5.8% higher at $13.17. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19.9% loss over the past four weeks.
Adaptive Biotechnologies’ stock price gain can be attributed to the positive investor mindset regarding the potential of its pipeline. The company is advancing a portfolio focused on immune-profiling diagnostics and immune-driven drug discovery. Its lead commercial product, clonoSEQ, is used to monitor minimal residual disease in hematologic cancers such as multiple myeloma and leukemia, and the company continues to expand its clinical adoption and regulatory indications. Additionally, the company’s Immune Medicine platform aims to discover T-cell receptor-based therapeutics targeting infectious diseases, cancer and autoimmune conditions. The company is also progressing research programs to identify disease-specific immune responses, which could support future diagnostics and therapeutic development.
This life-sciences research company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of +20%. Revenues are expected to be $61.84 million, up 17.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Adaptive Biotechnologies, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ADPT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Adaptive Biotechnologies is part of the Zacks Medical - Biomedical and Genetics industry. AnaptysBio, Inc. (ANAB - Free Report) , another stock in the same industry, closed the last trading session 1.6% higher at $64.81. ANAB has returned 16.2% in the past month.
For AnaptysBio, the consensus EPS estimate for the upcoming report has changed +34.5% over the past month to -$0.72. This represents a change of +43.8% from what the company reported a year ago. AnaptysBio currently has a Zacks Rank of #3 (Hold).